Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Aspirin use continues to surge among older adults in US

Aspirin use continues to surge among older adults in US

New research links sleep apnea, heavy snoring with premature cognitive decline

New research links sleep apnea, heavy snoring with premature cognitive decline

Autophagy: A new approach to fighting tuberculosis

Autophagy: A new approach to fighting tuberculosis

Novel findings may hold promise for children, adults with mitochondrial disorders

Novel findings may hold promise for children, adults with mitochondrial disorders

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Arts and craft activities, computer use may stave off memory problems

Arts and craft activities, computer use may stave off memory problems

Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

U-M's Taubman Institute receives $3 million gift to support next generation of medical research

U-M's Taubman Institute receives $3 million gift to support next generation of medical research

A new amyloid-targeting treatment for Alzheimer's disease

A new amyloid-targeting treatment for Alzheimer's disease

Research shows that hippocampus is dedicated to memory formation, not to spatial skills

Research shows that hippocampus is dedicated to memory formation, not to spatial skills

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

Study suggests possible role for caffeine in AD treatment

Study suggests possible role for caffeine in AD treatment

Complete review of amyloid-beta protein behind Alzheimer's disease

Complete review of amyloid-beta protein behind Alzheimer's disease

Study finds link between brain alterations and functional decline in women at risk for Alzheimer's disease

Study finds link between brain alterations and functional decline in women at risk for Alzheimer's disease

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Big data helps discover gephyrin protein's connection in human history

Big data helps discover gephyrin protein's connection in human history

Researchers present new studies on cognition and reasoning at CNS conference in San Francisco

Researchers present new studies on cognition and reasoning at CNS conference in San Francisco

Discovery opens new drug development avenues for treating multiple diseases

Discovery opens new drug development avenues for treating multiple diseases

Study: Blood test may help diagnose Fragile X syndrome related disorders in women

Study: Blood test may help diagnose Fragile X syndrome related disorders in women

UW Medicine receives $6 million from Ellison Foundation to revolutionize care for people with Alzheimer's

UW Medicine receives $6 million from Ellison Foundation to revolutionize care for people with Alzheimer's

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.